Chemical Messenger News and Research

RSS

Possible treatment for Fragile X syndrome

The first evidence for a possible treatment for Fragile X syndrome, one of the leading inherited causes of mental retardation, has emerged from experiments with a mutant fruit fly that exhibits characteristics of the disorder.

2 Mar 2005

Key insight into the process of normal synapse development may lead to improved treatment of conditions such as drug addiction and epilepsy

Communication in the brain travels from one nerve cell to another through critical connections called synapses. These neuron-to-neuron junctions form early in brain development, and their construction was thought to be guided by the nerve cells themselves.

13 Feb 2005

Mutant gene that starves the brain of serotonin 10 times more prevalent in depressed patients

A mutant gene that starves the brain of serotonin, a mood-regulating chemical messenger, has been discovered and found to be 10 times more prevalent in depressed patients than in control subjects, report researchers funded by the National Institutes of Health’s National Institute of Mental Health (NIMH) and National Heart Lung and Blood Institute (NHLBI).

21 Dec 2004

Instead of chemotherapy, drugs that influence the X protein's behavior might become an alternative cancer therapy

Identifying the link between chronic hepatitis B infection and liver cancer may one day help cancer patients sidestep the poison of chemotherapy, a Purdue University study suggests.

13 Dec 2004

Newly discovered genetic defect might represent an important risk factor for major depression

A newly discovered genetic defect might represent an important risk factor for major depression, a condition which effects 20 million people in the U.S., according to Duke University Medical Center researchers.

13 Dec 2004

New class of drugs to repair psychiatric disorders

“Smart” drugs capable of targeting specific brain cells to control psychiatric disorders such as autism and schizophrenia may be ready for early clinical trials within three years, with the launch of a $1.5 million project to take place at the Brain Research Centre (BRC)

29 Nov 2004

Dementia patients receiving long-term treatment with Reminyl may be able to stay at home for longer compared

Shire Pharmaceuticals Group has announced that Dementia patients receiving long-term treatment with Reminyl (more than 36 months) may be able to stay at home for longer compared to those receiving treatment for shorter periods of time.

10 Nov 2004

alpha4 may prove to be useful target for smoking addiction therapies

Nicotine is responsible for more than four million smoking-related deaths each year. Yet people still smoke. Why? One reason is the stranglehold of addiction, started when nicotine enhances the release of a neurotransmitter called dopamine

4 Nov 2004

Drinking regular cuppas could help improve your memory

Results of laboratory tests by a team from the University of Newcastle upon Tyne found that green and black tea inhibit the activity of certain enzymes in the brain which are associated with memory.

25 Oct 2004

Discovery of fundamental mechanism within cells that link obesity and type 2 diabetes

Researchers from the Harvard School of Public Health have discovered what they believe is the fundamental mechanism within cells that links two fast-rising public health threats: obesity and Type 2 diabetes.

18 Oct 2004

Highly concentrated solution of chemical messengers could block male to female HIV transmission

Researchers in the U.S have shown that it may be possible to block the transmission of the HIV virus from a man to a woman by using a highly concentrated solution of chemical messengers that attract white blood cells to the site of infection.

16 Oct 2004

Scientists develop rapid-fire tests for botulinum toxin

Scientists at the University of Wisconsin-Madison have developed a pair of rapid-fire tests for botulinum toxin, a feat that could underpin new technologies to thwart bioterrorism and spur the development of agents to blunt the toxic action of the world's most poisonous substance.

29 Sep 2004

New gene therapy technique may help treat Alzheimer's disease

Investigators at Rush University Medical Center have successfully initiated a new technique that uses gene therapy to deliver nerve growth factor into regions of the brain where neurons are degenerating, in order to prevent cell death and reverse cell atrophy, two hallmarks of Alzheimer's disease.

21 Sep 2004

Relationship between brain chemical messenger glutamate and schizophrenia traits

Researchers at the NIH's National Institute of Mental Health (NIMH) have identified a relationship between a small section of one gene, the brain chemical messenger glutamate, and a collection of traits known to be associated with schizophrenia.

15 Aug 2004

Gene responsible for management of glutamate is a promising candidate in determining risk for schizophrenia

Researchers at the National Institute of Mental Health have identified a relationship between a small section of one gene, the brain chemical messenger glutamate, and a collection of traits known to be associated with schizophrenia.

11 Aug 2004

New screening tool prevents wrong patients from receiving Parkinson's surgery

The allure of a new brain surgery technique to relieve the stiffness and shaking caused by Parkinson’s disease may lead to unnecessary operations, University of Florida researchers say, but a new screening tool they developed could prevent potentially dangerous procedures.

9 Aug 2004

Overactive brain circuit brings on depression

A brain imaging study by the NIH's National Institute of Mental Health (NIMH) has found that an emotion-regulating brain circuit is overactive in people prone to depression – even when they are not depressed.

5 Aug 2004

Switches in the brain that tell the body to stop eating and start burning calories

A Brown-led research team has discovered a pair of universal switches in the brain that tell the body to stop eating and start burning calories.

3 Aug 2004

Botox approved as treatment for severe underarm sweating

The FDA has approved Botulinum Toxin Type A (Botox) to treat severe underarm sweating known as “primary axillary hyperhidrosis” that cannot be managed by topical agents such as prescription antiperspirants. Botox has already been approved for several other purposes.

20 Jul 2004

Identification of a naturally occurring genetic difference that controls the production of serotonin in the brain

Researchers at Duke University Medical Center have provided the first direct evidence in mice for the role of an enzyme that specifically controls the production of serotonin in the brain.

8 Jul 2004